A World Report published in The Lancet lays out why the newest Alzheimer's drugs have produced approval in some countries and rejection in others. The core disagreement is not about whether the drugs do anything, but whether their measurable clinical benefit is large enough to matter to patients once safety risks and price tags are weighed. Agencies including the US Food and Drug Administration and the UK's Medicines and Healthcare Products Regulatory Agency have repeatedly landed in a different place from the European Medicines Agency on that question.
The safety concern that dominates these debates is ARIA, or amyloid-related imaging abnormalities, the brain swelling and bleeding that can show up on scans of people taking amyloid-targeting drugs. Set against benefits the report characterizes as modest, and against high treatment costs, regulators are essentially making a judgment call about acceptable trade-offs - and reasonable agencies are reaching opposite conclusions.
For patients and families, the practical consequence is that access to these medicines now depends heavily on where you live. It also means that a drug's approval in one country should not be read as a verdict that it works well; it reflects one regulator's weighing of imperfect evidence.
The report points to where the field is heading next: drugs designed to be safer and to act on a broader set of disease mechanisms rather than amyloid alone, and trials that enroll people at high risk of Alzheimer's before symptoms appear. With global dementia cases projected to climb from 55 million in 2020 to 78 million by 2030, the pressure to get both the science and the regulatory judgments right is only growing.